Mar 12, 2018 7:00am EDT Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Programs Update
Feb 7, 2018 4:30pm EST Tonix Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor Conference in New York City
Jan 24, 2018 4:30pm EST Tonix Pharmaceuticals to Present at Noble Capital Markets’ Fourteenth Annual Investor Conference in Fort Lauderdale
Jan 23, 2018 7:00am EST Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya® (Cyclobenzaprine HCl Sublingual Tablets)
Jan 19, 2018 2:00pm EST Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus from Cell Culture)
Jan 3, 2018 7:00am EST Tonix Pharmaceuticals to Present at Sachs Associates Neuroscience Innovation Forum and Biotech Showcase 2018 in San Francisco
Dec 12, 2017 7:00am EST Tonix Pharmaceuticals Completes Positive Pre-IND Meeting with FDA for TNX-102 SL (Cyclobenzaprine HCI Sublingual Tablets) as a Clinical Candidate for Agitation in Alzheimer’s Disease
